Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Ivonescimab tops Keytruda with strong OS in PD-L1-high NSCLC
Ivonescimab delivered a particularly strong OS benefit in PD-L1-high patients, for whom Keytruda monotherapy remains the standard of care globally.
Angus Liu
Sep 13, 2026 8:00am
Failed Trodelvy first-line NSCLC trial shows better China data
Sep 12, 2026 9:45pm
Designing an agentic, future‑ready tech roadmap for emerging pharma
Brought to you by
ZS
AstraZeneca’s Etcamah flunks first-line breast cancer trial
Sep 12, 2026 12:43pm
Pharma marketers face privacy hurdles, turn to omnichannel strategies
Brought to you by
Swoop
Handa's Cabometyx formulation no threat to Exelixis: analysts
Sep 11, 2026 2:06pm
